Original Article

Cancer Chemotherapy and Pharmacology

, Volume 60, Issue 6, pp 821-829

First online:

Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts

  • Jonathan C. LowAffiliated withUrologic Sciences, The Prostate Center at Vancouver General HospitalPharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia
  • , Kishor M. WasanAffiliated withPharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia
  • , Ladan FazliAffiliated withUrologic Sciences, The Prostate Center at Vancouver General Hospital
  • , Andy EberdingAffiliated withUrologic Sciences, The Prostate Center at Vancouver General Hospital
  • , Hans AdomatAffiliated withUrologic Sciences, The Prostate Center at Vancouver General Hospital
  • , Emma S. GunsAffiliated withUrologic Sciences, The Prostate Center at Vancouver General Hospital Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors.

Methods

Three CsCl dose titration studies were completed in tumor-bearing and non-tumor-bearing athymic nude mice. All mice were administered either vehicle (controls), 150, 300, 600, 800, 1,000, or 1,200 mg/kg of CsCl once daily by oral gavage for 30 consecutive days. Body mass was measured daily, food and water consumption were measured every 2 days, and tumor volume was measured twice weekly. Histopathological analysis was conducted on tissues collected from each of the studies. Serum AST/ALT and creatinine were also measured.

Results

Administration of 800–1,200 mg/kg CsCl reduced PC-3 tumor growth but had no effect on LNCaP tumors. Administration of 800–1,200 mg/kg CsCl also resulted in increased water consumption, bladder crystal development, and higher prevalence of cardiac fibrin clots. An observed loss in body mass was dependent on the xenograft type and concentration of CsCl administered. CsCl did not affect serum AST/ALT and creatinine levels.

Conclusions

CsCl may have a therapeutic effect against prostate cancer, but one cannot overlook the acute toxicities also described.

Keywords

Cesium chloride Prostate cancer PC-3 tumor LNCaP tumor Acute toxicity